110 related articles for article (PubMed ID: 37341420)
1. The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer.
Joyce DD; Qin X; Sharma V; Boorjian SA; Barocas DA; Dusetzina SB; Moses KA
J Urol; 2023 Sep; 210(3):447-453. PubMed ID: 37341420
[TBL] [Abstract][Full Text] [Related]
2. Association between insurance cost-sharing subsidy and postoperative opioid prescription refills among Medicare patients.
Kirsch M; Montgomery JR; Hu HM; Englesbe M; Hallstrom B; Brummett CM; Fendrick AM; Waljee JF
Surgery; 2020 Aug; 168(2):244-252. PubMed ID: 32505547
[TBL] [Abstract][Full Text] [Related]
3. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
4. Association between low-income subsidies and inequities in orally administered antimyeloma therapy use.
Jazowski SA; Samuel-Ryals CA; Wood WA; Zullig LL; Trogdon JG; Dusetzina SB
Am J Manag Care; 2023 May; 29(5):246-254. PubMed ID: 37229783
[TBL] [Abstract][Full Text] [Related]
5. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
6. Cancer outcomes in low-income elders: is there an advantage to being on Medicaid?
Koroukian SM; Bakaki PM; Owusu C; Earle CC; Cooper GS
Medicare Medicaid Res Rev; 2012; 2(2):. PubMed ID: 24800139
[TBL] [Abstract][Full Text] [Related]
7. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
8. The Association Between Medicare Low-Income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer.
Chou YT; Farley JF; Stinchcombe TE; Proctor AE; Lafata JE; Dusetzina SB
J Natl Cancer Inst; 2020 Jun; 112(6):637-646. PubMed ID: 31501872
[TBL] [Abstract][Full Text] [Related]
9. The unintended effects of the Medicare Part D low income subsidy.
Decarolis F
Health Policy; 2015 May; 119(5):597-603. PubMed ID: 25716285
[TBL] [Abstract][Full Text] [Related]
10. The relationship between the low-income subsidy and cost-related nonadherence to drug therapies in Medicare Part D.
Wei II; Lloyd JT; Shrank WH
J Am Geriatr Soc; 2013 Aug; 61(8):1315-23. PubMed ID: 23889465
[TBL] [Abstract][Full Text] [Related]
11. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
Joyce DD; Sharma V; Jiang DH; Van Houten HK; Sangaralingham LR; Borah BJ; Kwon ED; Penson DF; Dusetzina SB; Tilburt JC; Boorjian SA
J Urol; 2022 Nov; 208(5):987-996. PubMed ID: 36094864
[TBL] [Abstract][Full Text] [Related]
12. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
[TBL] [Abstract][Full Text] [Related]
13. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
Yusuf AA; Howell BL; Powers CA; St Peter WL
Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
[TBL] [Abstract][Full Text] [Related]
14. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
15. The Medicare drug benefit: update on the low-income subsidy.
Stahlman ME
Issue Brief George Wash Univ Natl Health Policy Forum; 2009 Jul; (833):1-22. PubMed ID: 19685590
[TBL] [Abstract][Full Text] [Related]
16. The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.
Hartung DM; Johnston KA; McGregor JC; Bourdette DN
Mult Scler Relat Disord; 2020 Nov; 46():102554. PubMed ID: 33032059
[TBL] [Abstract][Full Text] [Related]
17. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
Stuart B; Hendrick FB; Xu J; Dougherty JS
Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
[TBL] [Abstract][Full Text] [Related]
18. Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018.
Li M; Bounthavong M
J Manag Care Spec Pharm; 2021 Dec; 27(12):1750-1756. PubMed ID: 34818087
[No Abstract] [Full Text] [Related]
19. Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy.
Briesacher BA; Ross-Degnan D; Wagner AK; Fouayzi H; Zhang F; Gurwitz JH; Soumerai SB
Med Care; 2010 Jun; 48(6):503-9. PubMed ID: 20473197
[TBL] [Abstract][Full Text] [Related]
20. Cognition and take-up of subsidized drug benefits by Medicare beneficiaries.
Kuye IO; Frank RG; McWilliams JM
JAMA Intern Med; 2013 Jun; 173(12):1100-7. PubMed ID: 23649604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
